DK2800579T3 - Kapsler indeholdende olie-baserede flydende sammensætninger af kombinerede terapeutiske stoffer til behandling af diabetes - Google Patents

Kapsler indeholdende olie-baserede flydende sammensætninger af kombinerede terapeutiske stoffer til behandling af diabetes

Info

Publication number
DK2800579T3
DK2800579T3 DK13733831.5T DK13733831T DK2800579T3 DK 2800579 T3 DK2800579 T3 DK 2800579T3 DK 13733831 T DK13733831 T DK 13733831T DK 2800579 T3 DK2800579 T3 DK 2800579T3
Authority
DK
Denmark
Prior art keywords
liquid compositions
containing oil
based liquid
capsules containing
combined therapeutics
Prior art date
Application number
DK13733831.5T
Other languages
English (en)
Inventor
Miriam Kidron
Original Assignee
Oramed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oramed Ltd filed Critical Oramed Ltd
Application granted granted Critical
Publication of DK2800579T3 publication Critical patent/DK2800579T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK13733831.5T 2012-01-03 2013-01-03 Kapsler indeholdende olie-baserede flydende sammensætninger af kombinerede terapeutiske stoffer til behandling af diabetes DK2800579T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261631339P 2012-01-03 2012-01-03
PCT/IL2013/050007 WO2013102899A1 (en) 2012-01-03 2013-01-03 Methods and compositions for treating diabetes

Publications (1)

Publication Number Publication Date
DK2800579T3 true DK2800579T3 (da) 2017-11-13

Family

ID=48745016

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13733831.5T DK2800579T3 (da) 2012-01-03 2013-01-03 Kapsler indeholdende olie-baserede flydende sammensætninger af kombinerede terapeutiske stoffer til behandling af diabetes

Country Status (9)

Country Link
US (5) US10398762B2 (da)
EP (2) EP2800579B1 (da)
JP (1) JP6174601B2 (da)
CN (2) CN104159598A (da)
DK (1) DK2800579T3 (da)
ES (1) ES2644962T3 (da)
HK (2) HK1203826A1 (da)
NO (1) NO2898107T3 (da)
WO (1) WO2013102899A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2462117T3 (es) * 2005-09-06 2014-05-22 Oramed Pharmaceuticals Inc. Métodos y composiciones para la administración oral de proteínas
CN102037121B (zh) 2008-03-26 2013-07-10 奥拉姆德有限公司 用于口服给予蛋白质的方法和组合物
AU2009245294B2 (en) 2008-05-05 2014-02-20 Oramed Ltd. Methods and compositions for oral administration of exenatide
EP2800579B1 (en) 2012-01-03 2017-08-30 Oramed Ltd. Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes
ES2912138T3 (es) * 2012-02-01 2022-05-24 Oramed Ltd Composiciones que contienen inhibidores de proteasa, composiciones que comprenden las mismas y métodos para producir y usar las misma
CN110151979A (zh) * 2013-01-03 2019-08-23 奥拉姆德有限公司 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物
MY194604A (en) 2013-03-13 2022-12-06 Takeda Pharmaceuticals Co Guanidinobenzoic acid ester compound
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US10039810B2 (en) 2014-05-15 2018-08-07 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising anti-interleukin antibodies
WO2020130649A1 (ko) * 2018-12-19 2020-06-25 대화제약 주식회사 Glp-1 유사체를 포함하는 경구투여용 약제학적 조성물
CN113171446B (zh) * 2021-05-06 2022-03-29 合肥天汇孵化科技有限公司 利拉鲁肽组合物及其用途
US20240366731A1 (en) * 2021-08-12 2024-11-07 Celagenex Research (India) Pvt. Ltd. Oral algal oil based gastro-intestinal tract permeable peptide composition

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS6350793A (ja) 1986-08-20 1988-03-03 株式会社東芝 高速増殖炉の崩壊熱除去システム
US5034415A (en) 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
EP0351651B1 (en) * 1988-07-21 1993-09-15 F. Hoffmann-La Roche Ag Insulin preparation
JPH02250823A (ja) 1989-03-24 1990-10-08 Tsumura & Co マイクロカプセル剤およびその製造方法
GB9007052D0 (en) 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
IL114673A (en) 1995-07-19 2000-12-06 Hadasit Med Res Service Pharmaceutical compositions containing protein for oral administration
JPH09208485A (ja) 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
JPH10330287A (ja) 1997-03-31 1998-12-15 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤
JP2000128805A (ja) 1998-10-27 2000-05-09 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸および高分子ゲルからなる経粘膜吸収促進剤及びそれを含有する薬剤
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
JP2001240558A (ja) 2000-02-29 2001-09-04 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
KR20010069322A (ko) 2001-03-08 2001-07-25 서종수 휴대형정보단말기 또는 화상이동통신장치를 이용한전자경매방법
KR20010069433A (ko) 2001-03-22 2001-07-25 김윤완 노루궁뎅이버섯을 이용한 건강 보조 식품
CN1160122C (zh) * 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
WO2003007976A1 (en) 2001-07-18 2003-01-30 Solae, Llc High protein, bowman-birk inhibitor concentrate and process for its manufacture
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
MXPA06011871A (es) 2004-04-15 2007-10-08 Chiasma Inc Composiciones capaces de facilitar la penetracion a traves de una barrera biologica.
PT2626368T (pt) 2004-07-19 2017-03-10 Biocon Ltd Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
WO2006025882A2 (en) * 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
ES2462117T3 (es) 2005-09-06 2014-05-22 Oramed Pharmaceuticals Inc. Métodos y composiciones para la administración oral de proteínas
US20070086972A1 (en) 2005-09-12 2007-04-19 Jacob Birnbaum Hair growth compositions and methods for treating hair loss or related conditions
US20070077283A1 (en) 2005-09-30 2007-04-05 Nastech Pharmaceutical Company Inc. Method of enhancing transmucosal delivery of therapeutic compounds
CN101095942B (zh) 2006-06-30 2011-11-16 北京民海生物科技有限公司 一种包含稳定剂的Exendin-4注射剂药物配方
CN102037121B (zh) 2008-03-26 2013-07-10 奥拉姆德有限公司 用于口服给予蛋白质的方法和组合物
AU2009245294B2 (en) 2008-05-05 2014-02-20 Oramed Ltd. Methods and compositions for oral administration of exenatide
JP2011526888A (ja) 2008-07-01 2011-10-20 ザ・ジョンズ・ホプキンス・ユニバーシティ 治療薬を標的送達するための経口速溶性薄膜
EP2331072B8 (en) 2008-08-18 2020-08-26 Entera Bio Ltd. Methods and compositions for oral administration of proteins
EP2800579B1 (en) 2012-01-03 2017-08-30 Oramed Ltd. Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes
ES2912138T3 (es) 2012-02-01 2022-05-24 Oramed Ltd Composiciones que contienen inhibidores de proteasa, composiciones que comprenden las mismas y métodos para producir y usar las misma
CN110151979A (zh) 2013-01-03 2019-08-23 奥拉姆德有限公司 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物
EP3801595A1 (en) 2018-06-11 2021-04-14 Oramed Ltd. Recombinant protease inhibitor-containing compositions, methods for producing same and uses thereof

Also Published As

Publication number Publication date
CN104159598A (zh) 2014-11-19
NO2898107T3 (da) 2018-09-08
EP3260131A1 (en) 2017-12-27
JP2015503578A (ja) 2015-02-02
WO2013102899A1 (en) 2013-07-11
EP2800579B1 (en) 2017-08-30
CN108904810A (zh) 2018-11-30
HK1251796A1 (zh) 2019-03-15
US10398762B2 (en) 2019-09-03
EP2800579A1 (en) 2014-11-12
ES2644962T3 (es) 2017-12-01
US20190374615A1 (en) 2019-12-12
US20230210956A1 (en) 2023-07-06
HK1203826A1 (en) 2015-11-06
US20210077588A1 (en) 2021-03-18
JP6174601B2 (ja) 2017-08-02
US11395848B2 (en) 2022-07-26
EP2800579A4 (en) 2015-08-19
US20240299503A1 (en) 2024-09-12
US20150017238A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
DK2800579T3 (da) Kapsler indeholdende olie-baserede flydende sammensætninger af kombinerede terapeutiske stoffer til behandling af diabetes
HK1255605A1 (zh) 新液體組合物的增强的穩定性
CO6852068A2 (es) Formulación líquida estable de etanercept
DK3156056T3 (da) Farmaceutiske sammensætninger der består af sorbitanestere
DK2877012T3 (da) Herbicide sammensætninger der omfatter 4-amino-3-chlor-5-fluor-6-(4-chlor-2-fluor-3-methoxyphenyl)-pyridin-2-carboxylsyre
SI2854768T1 (sl) Farmacevtski sestavki pemetrekseda
DK2925636T3 (da) Beholder med styreelement til klæbemiddel
DK2800571T3 (da) Oromukosale flydende østradiolsammensætninger
DK2822568T3 (da) Anvendelser af caseinsammensætninger
EP2812279A4 (en) LIQUID PHASE SYNTHESIS OF TRISILYLAMINE
HK1208177A1 (en) Racecadotril liquid compositions
PT2935471T (pt) Composições líquidas curáveis
PL2887924T3 (pl) Kompozycje farmaceutyczne etorykoksybu
GB201201162D0 (en) Liquid cosmetic composition
DK2888228T3 (da) Inhibitorer af CD40-TRAF6 interaktion
SMT201600419B (it) Composizione farmaceutica contenente fosfolipidi
CR20130037A (es) Composición farmacéutica de liberación prolongada de trimetazidina
DK2844623T3 (da) Fremgangsmåder til fremstilling af perlitholdige byggematerialer
IL233939B (en) Liquid formulations of hypoglycemic sulfonamides
DK2814462T3 (da) Oliebaseret farmaceutisk sammensætning til behandling af gastrointestinale sygdomme
FR2988587B1 (fr) Composition auto-emulsionnante
EP2884964A4 (en) PHARMACEUTICAL COMPOSITION OF PROPOFOL
EP2884963A4 (en) STABLE PHARMACEUTICAL FORMULATION OF CABAZITAXEL
DE102011003344A8 (de) Flüssigkeitspatrone
UA23587S (uk) Набір графічних інтерфейсів